Literature DB >> 12932353

Regulation by C5a of neutrophil activation during sepsis.

Niels C Riedemann1, Ren-Feng Guo, Kurt D Bernacki, Jayne S Reuben, Ines J Laudes, Thomas A Neff, Hongwei Gao, Cecilia Speyer, Vidya J Sarma, Firas S Zetoune, Peter A Ward.   

Abstract

In sepsis, there is evidence that excessive C5a generation leads to compromised innate immune functions, being associated with poor outcome. We now report that in vitro exposure of neutrophils to C5a causes increased levels of IkappaBalpha, decreased NF-kappaB-dependent gene transcription of TNFalpha, and decreased lipopolysaccharide (LPS)-induced TNFalpha production. Similar findings were obtained with neutrophils from cecal ligation/puncture (CLP)-induced septic rats. Such changes were reversed by antibody-induced in vivo blockade of C5a. In contrast, in vitro exposure of alveolar macrophages to C5a and LPS resulted in enhanced production of TNFalpha and no increase in IkappaBalpha. These data suggest that CLP-induced sepsis causes a C5a-dependent dysfunction of neutrophils, which is characterized by altered signaling associated with NF-kappaB activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932353     DOI: 10.1016/s1074-7613(03)00206-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  52 in total

Review 1.  A noninflammatory pathway for pregnancy loss: innate immune activation?

Authors:  Jane E Salmon
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

2.  Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis.

Authors:  Markus Bosmann; J Vidya Sarma; Gelareh Atefi; Firas S Zetoune; Peter A Ward
Journal:  FASEB J       Date:  2011-12-27       Impact factor: 5.191

3.  Differential pharmacological behaviour of p38 inhibitors in regulating the LPS-induced TNF-α production in human and rat whole blood in vitro.

Authors:  Mercè Pont-Giralt; Núria Godessart; Cristina Balagué
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

4.  A metalloproteinase karilysin present in the majority of Tannerella forsythia isolates inhibits all pathways of the complement system.

Authors:  Monika Jusko; Jan Potempa; Abdulkarim Y Karim; Miroslaw Ksiazek; Kristian Riesbeck; Peter Garred; Sigrun Eick; Anna M Blom
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 5.  New insights into cellular mechanisms during sepsis.

Authors:  Laszlo M Hoesel; Hongwei Gao; Peter A Ward
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 6.  The role of complement in inflammatory diseases from behind the scenes into the spotlight.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

Review 7.  Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host.

Authors:  Jennifer L Krauss; Jan Potempa; John D Lambris; George Hajishengallis
Journal:  Periodontol 2000       Date:  2010-02       Impact factor: 7.589

8.  Dexamethasone suppresses interleukin-22 associated with bacterial infection in vitro and in vivo.

Authors:  E Ziesché; P Scheiermann; M Bachmann; C D Sadik; C Hofstetter; B Zwissler; J Pfeilschifter; H Mühl
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

9.  Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis.

Authors:  Katja Dahlke; Christiane D Wrann; Oliver Sommerfeld; Maik Sossdorf; Peter Recknagel; Svea Sachse; Sebastian W Winter; Andreas Klos; Gregory L Stahl; Yuanyuan Xu Ma; Ralf A Claus; Konrad Reinhart; Michael Bauer; Niels C Riedemann
Journal:  J Immunol       Date:  2011-01-24       Impact factor: 5.422

10.  Novel chemokine responsiveness and mobilization of neutrophils during sepsis.

Authors:  Cecilia L Speyer; Hongwei Gao; Nicholas J Rancilio; Thomas A Neff; Gary B Huffnagle; J Vidya Sarma; Peter A Ward
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.